CoChat
Sign Up
Cited by 29

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume

Tabatabaei-Jafari, Hossein, Shaw, Marnie E., Walsh, Erin, Cherbuin, Nicolas·2019·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2019.08.033
Open this paper in CoChat — free account

Abstract

A key question for the design of clinical trials for Alzheimer's disease (AD) is whether the timing of conversion from mild cognitive impairment (MCI) to AD can be predicted. This is also an important question for the clinical management of MCI. This study aims to address this question by exploring the contribution of baseline brain volume and annual volume change, using Cox regression, in predicting the time to conversion. Individuals with MCI, who converted to AD (n = 198), reverted to normal (n = 38), or remained stable (n = 96) for at least five years, were included in this study. The results revealed that the volumes of all the brain areas considered were predictive of the time to conversion from MCI to AD. Annual change in volume was also predictive of the time to conversion but only when initial volumes were above a certain threshold. This is important because it suggests that reduction in atrophy rate, which is the outcome of some clinical trials, is not inevitably associated with delay in conversion from MCI to AD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2019.08.033

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cortical thickness is key to assessing brain atrophy in AD, with age-related decreases closely linked to cognitive and memory impairments as well as AD conversion.

    “Specifically, cortical thickness (CTh) is key to assessing brain atrophy in AD, with age-related decreases closely linked to cognitive and memory impairments [18] as well as AD conversion [21, 22].”

    From Association of APOC1 with cortical atrophy during conversion to Alzheimer’s disease (2025) · cites this paper as [22]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 270, 10.1016/j.jalz.2011.03.008 · DOI · Paper page
  2. Braak, 1997, Frequency of stages of Alzheimer-related lesions in different age categories, Neurobiol. Aging, 18, 351, 10.1016/S0197-4580(97)00056-0 · DOI · Paper page
  3. Byun, 2015, Heterogeneity of regional brain atrophy patterns associated with distinct progression rates in Alzheimer's disease, PLoS One, 10, e0142756, 10.1371/journal.pone.0142756 · DOI
  4. Douaud, 2013, Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment, Proc. Natl. Acad. Sci. U. S. A., 110, 9523, 10.1073/pnas.1301816110 · DOI
  5. Dubois, 2015, Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease, Alzheimers Dement., 11, 1041, 10.1016/j.jalz.2014.10.003 · DOI
  6. Falahati, 2017, Monitoring disease progression in mild cognitive impairment: associations between atrophy patterns, cognition, APOE and amyloid, Neuroimage Clin., 16, 418, 10.1016/j.nicl.2017.08.014 · DOI
  7. Ferreira, 2017, Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications, Sci. Rep., 7, 46263, 10.1038/srep46263 · DOI
  8. Fjell, 2014, Accelerating cortical thinning: unique to dementia or universal in aging?, Cereb. Cortex, 24, 919, 10.1093/cercor/bhs379 · DOI
  9. Gavidia-Bovadilla, 2017, Early prediction of Alzheimer's disease using null longitudinal model-based classifiers, PLoS One, 12, e0168011, 10.1371/journal.pone.0168011 · DOI
  10. Jack, 2008, The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods, J. Magn. Reson. Imaging, 27, 685, 10.1002/jmri.21049 · DOI · Paper page
  11. Jack, 2005, Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI, Neurology, 65, 1227, 10.1212/01.wnl.0000180958.22678.91 · DOI · Paper page
  12. Kile, 2017, IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia, J. Neurol. Neurosurg. Psychiatry, 88, 106, 10.1136/jnnp-2015-311486 · DOI
  13. Kobe, 2016, Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment, Neuroimage, 131, 226, 10.1016/j.neuroimage.2015.09.050 · DOI
  14. Li, 2012, Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features, Neurobiol. Aging, 33, 427.e15, 10.1016/j.neurobiolaging.2010.11.008 · DOI
  15. Liu, 2017, Prediction of mild cognitive impairment conversion using a combination of independent component analysis and the Cox model, Front Hum. Neurosci., 11, 33, 10.3389/fnhum.2017.00033 · DOI
  16. McEvoy, 2011, Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive Prognosis1, Radiology, 259, 834, 10.1148/radiol.11101975 · DOI
  17. Pintzka, 2015, Marked effects of intracranial volume correction methods on sex differences in neuroanatomical structures: a HUNT MRI study, Front Neurosci., 9, 238, 10.3389/fnins.2015.00238 · DOI
  18. Prins, 2014, The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial, Alzheimers Res. Ther., 6, 47, 10.1186/alzrt275 · DOI
  19. Risacher, 2010, Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort, Neurobiol. Aging, 31, 1401, 10.1016/j.neurobiolaging.2010.04.029 · DOI
  20. Tabatabaei-Jafari, 2015, Cerebral atrophy in mild cognitive impairment: a systematic review with meta-analysis, Alzheimers Dement., 1, 487
  21. Tabatabaei-Jafari, 2019, Cognitive/functional measures predict Alzheimer's disease, dependent on hippocampal volume, J. Gerontol. B Psychol. Sci. Soc. Sci.
  22. Teipel, 2015, The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - beyond classical regression, Neuroimage Clin., 8, 583, 10.1016/j.nicl.2015.05.006 · DOI
  23. Thal, 2002, Phases of A beta-deposition in the human brain and its relevance for the development of AD, Neurology, 58, 1791, 10.1212/WNL.58.12.1791 · DOI · Paper page
  24. Thung, 2018, Conversion and time-to-conversion predictions of mild cognitive impairment using low-rank affinity pursuit denoising and matrix completion, Med. Image Anal., 45, 68, 10.1016/j.media.2018.01.002 · DOI · Paper page
  25. Whitwell, 2012, Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study, Lancet Neurol., 11, 868, 10.1016/S1474-4422(12)70200-4 · DOI · Paper page
  26. Zhang, 2017, Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12-month randomized, double-blind, placebo-controlled trial, J. Alzheimers Dis., 55, 497, 10.3233/JAD-160439 · DOI

Cited by

Sorted by citations

Metadata

Authors
Tabatabaei-Jafari, H., Shaw, M. E., Walsh, E., & Cherbuin, N.
ORCID
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2019-11
Volume
83
Pages
86-94
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2019.08.033
Cited by
29
References
7
Language
en
Licence
Funders
  • ADNI; National Institutes of Health (U01 AG024904)
  • ADNI
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • Alzheimer’s Association; Alzheimer Drug Discovery Foundation
  • Canadian Institutes of Health Research
  • ADNI clinical sites in Canada
  • National Computational Infrastructure
  • Australian
  • Australian Government Research Training Program

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review